We aim to influence policy developments so that researchers can be as effective as possible and health can be improved.
We work with a wide range of partners – including governments, research funders, learned societies, charities and commercial organisations – in the UK, Europe and globally.
Head of UK and EU Policy
PA and Team Coordinator
EU and Public Affairs Manager
Brexit, public affairs, relationship management, EU health and research policy.
Policy Adviser (on secondment)
UK research investment, funding structures, Research Excellence Framework, What’s it Worth studies.
emerging science and technologies, regulation.
immigration, innovation policy, All-Party Parliamentary Group on Medical Research, parliamentary communications, diversity, education and skills.
Head of Global Policy
general enquiries for Global Policy, cultural engagement.
access to healthcare interventions (general), epidemic preparedness, sustainable development goals.
access to healthcare interventions (products), research uptake.
access to healthcare interventions (general), research uptake.
emerging science and technologies, research uptake.
Lorenzo De Santis
research and development, innovation, access to healthcare interventions.
epidemic preparedness, sustainable development goals, vaccines.
Wellcome is working with the World Health Organization (WHO) to take on big challenges in global health.
New clinical practice guidelines are urgently needed for trials where the current guidelines are not fit for purpose.
Everyone should have access to the life-changing benefits of medicines and other healthcare interventions, like vaccines, diagnostics and therapies.
We want the research we fund – like publications, data, software and materials – to be open and accessible, so it can have the greatest possible impact.
We're working with the UK government and others to achieve a Brexit settlement that allows research to thrive in the UK and Europe.
Emerging science and technologies, such as human genome editing and gene drive, could provide new solutions to health problems.
Patient data is hugely valuable for research. But the value of that data can only be unlocked if concerns about patient privacy are taken seriously.
Government investment plays an important part in supporting scientific excellence in the UK.
Research is an essential part of being ready for and responding to public health emergencies.
The European General Data Protection Regulation was agreed in April 2016 and took effect from 25 May 2018.
The European Commission has published a proposal to update EU copyright law so that it applies equally across Europe and is fit for purpose in the 21st century.
Almost every major breakthrough in human and veterinary medicine has depended on the use of animals to research, develop or test new therapies.
Mitochondrial donation is an IVF technique that gives families affected by mitochondrial disease the chance of having healthy children.
The European Union is revising regulations governing the manufacture and sale of medical devices.
The Expert Advisory Group on Data Access promoted good working practices, consistent governance and transparent decision making for managing and using data from cohort studies.
Good research practice is one of the foundations of high-quality research.
The recommendations set out in the review mark one of the first steps towards making sure that promising drugs, devices, diagnostics and digital products are adopted quickly across the NHS.
A blueprint for dynamic oversight: how the UK can take a global lead in emerging science and technologies [PDF 720KB]
Effective regulatory oversight is needed to make sure emerging science and technologies reach their full potential quickly and safely, and with the public's trust. Our report sets out how the UK can become a world leader in this area.
[Summary] Effective regulatory oversight is needed to make sure emerging science and technologies reach their full potential quickly and safely, and with the public's trust. Our report sets out how the UK can become a world leader in this area.
Our workshop with the Gates Foundation and the Academy of Medical Sciences looked at how the current guidelines for clinical trials could be improved, and possible alternative approaches.